Marqibo Approved for Treatment of Philadelphia-Negative ALL
20:01 EDT 16 Aug 2012 | Cancer Connect
The U.S. Food and Drug Administration (FDA) has approved Marqibo® (vincristine sulfate liposome injection) to treat adults with Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL) whose leukemia has returned or progressed follo..
Original Article: Marqibo Approved for Treatment of Philadelphia-Negative ALL
More From BioPortfolio on "Marqibo Approved for Treatment of Philadelphia-Negative ALL"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
